Scinai Reports Q1 2026 Results and Expansion of CDMO Platform via Recipharm Acquisition

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) reported financial results for the first quarter ended March 31, 2026. Revenues were $489 thousand, down from $586 thousand in the prior year, though the quarter included new revenue from the recently acquired Recipharm Israel facility. The company reported a net profit of $3.58 million, a significant turnaround from a $1.56 million loss in Q1 2025, primarily driven by a $6.16 million non-cash bargain purchase gain from the Recipharm acquisition. Operationally, Scinai completed the acquisition of Recipharm Israel, adding a second manufacturing site and establishing a strategic CDMO collaboration with Recipharm AB. The company prioritized its systemic IL-17 bispecific antibody as the lead program for its NanoAb platform. Scinai is aggressively pursuing non-dilutive funding, with several grant decisions from Polish FENG and the Israel Innovation Authority expected in the second half of 2026. Cash and equivalents stood at $3.11 million as of March 31, 2026.